Get started
Author

V.Y.M. Heong

Efficacy and safety of cobimetinib (cobi) and atezolizumab (atezo) in an expanded phase 1b study of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC)
2016 · J. Desai, Y.S. Hong, et al. · Annals of Oncology · 7
PDF
RAS/AKT pathway mutations as predictive biomarkers in patients with colorectal cancer treated with the exportin 1 (XPO1) inhibitor selinexor (SEL) – inhibition of nuclear-cytoplasmic translocation of p27 as a mechanism of anti-tumour activity
2016 · V.Y.M. Heong, P. Koe, et al. · Annals of Oncology · 6
Phase Ib study of safety and tolerability of selinexor in Asian patients with advanced solid cancers
2018 · V.Y.M. Heong, M.L. Goh, et al. · Annals of Oncology · 3
54O Safety outcomes by UGT1A1 status in the phase III TROPiCS-02 study of sacituzumab govitecan (SG) in HR+/HER2– metastatic breast cancer (mBC)
2023 · V.Y.M. Heong, F. Marmé, et al. · Annals of Oncology · 2
PDF
753P Unlocking the circulating immune landscape of advanced clear-cell ovarian cancer: Insights from the MOCCA trial
2024 · F. Blanc-Durand, N. Ngoi, et al. · Annals of Oncology · 1
Phase I study of low dose whole abdominal radiation therapy (LDWART) in combination with weekly paclitaxel (wP) for platinum resistant ovarian cancer (PROC)
2019 · N.Y.L. Ngoi, V.Y.M. Heong, et al. · Annals of Oncology · 1
PDF
177RO Regulatory approval delays for pembrolizumab and trastuzumab deruxtecan across the Asia-Pacific region
2026 · Y.E. Xu, N. Hitchen, et al. · ESMO Open
PDF
100P Comprehensive genomic landscape of Asian and African breast cancer (BC) patients (pts)
2025 · V.Y.M. Heong, J.Y.S. Chan, et al. · ESMO Open
PDF
88O Improving access to clinical trials and novel therapeutics for advanced solid tumours in the Asia-Pacific Region: Insights from the ASTER study
2025 · P.K. Panda, F.I.L. Ting, et al. · ESMO Open
96P Application of an ex vivo functional precision medicine platform in breast cancer
2025 · J.J. Lim, M.M.A. Rashid, et al. · ESMO Open
PDF
Efficacy and tolerability of olaparib in Asian patients with recurrent ovarian, primary peritoneal or fallopian tube carcinoma: The National University Cancer Institute, Singapore experience
2018 · V.Y.M. Heong, Y.W. Lim, et al. · Annals of Oncology
Targeted approaches to C5 high-grade serous ovarian cancer through novel patient derived xenografts
2017 · V.Y.M. Heong · Minerva Access (University of Melbourne)
PDF
272PD BRCA1/2 mutation frequency and patterns of treatment response in Asian women with ovarian, primary peritoneal or fallopian tube carcinoma (OPFC): experience from an Asian cancer centre
2015 · V.Y.M. Heong, P.Y. Ong, et al. · Annals of Oncology
127O Phase 1 study of safety and tolerability of selinexor in Asian patients with advanced solid cancers: updated results
2015 · V.Y.M. Heong, P. Koe, et al. · Annals of Oncology
Works count: 14
Citation count: 20
H-index: 3
I10-index:
Year
Topic
Type